Obstructive sleep apnea-hypopnea (OSAH) is a common disorder characterized by recurrent collapse of the upper airway during sleep. Patients experience a reduced quality of life and an increased risk of motor vehicle crashes (MVCs). Continuous positive airway pressure (CPAP), which is the first-line therapy for OSAH, improves sleepiness, vigilance and quality of life.
To assess the cost-effectiveness of CPAP therapy versus no treatment for OSAH patients who are drivers.
A Markov decision analytical model with a five-year time horizon was used. The study population consisted of male and female patients, between 30 and 59 years of age, who were newly diagnosed with moderate to severe OSAH. The model evaluated the cost-effectiveness of CPAP therapy in reducing rates of MVCs and improving quality of life. Utility values were obtained from previously published studies. Rates of MVCs under the CPAP and no CPAP scenarios were calculated from Insurance Corporation of British Columbia data and a systematic review of published studies. MVCs, equipment and physician costs were obtained from the British Columbia Medical Association, published cost-of-illness studies and the price lists of established vendors of CPAP equipment in British Columbia. Findings were examined from the perspectives of a third-party payer and society.
From the third-party payer perspective, CPAP therapy was more effective but more costly than no CPAP (incremental cost-effectiveness ratio [ICER] of $3,626 per quality-adjusted life year). From the societal perspective, the ICER was similar ($2,979 per quality-adjusted life year). The ICER was most dependent on preference elicitation method used to obtain utility values, varying almost sixfold under alternative assumptions from the base-case analysis.
After considering costs and impact on quality of life, as well as the risk of MVCs in individuals with OSAH, CPAP therapy for OSAH patients is a highly efficient use of health care resources. Provincial governments who do not provide funding for CPAP therapy should reconsider.
Notes
Cites: Qual Life Res. 1998 Feb;7(2):95-1009523490
Cites: Chest. 1997 Dec;112(6):1561-69404754
Cites: Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1108-1410194153
Cites: Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-19215544708
Cites: Lancet. 2005 Mar 19-25;365(9464):1046-5315781100
Cites: Arch Intern Med. 2006 May 8;166(9):977-8416682570
Cites: Respir Med. 2000 Jan;94(1):87-9010714485
Cites: Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):857-910712333
Cites: Sleep. 2000 May 1;23(3):383-910811382
Cites: Annu Rev Public Health. 2000;21:587-61110884966
Cites: Scand J Work Environ Health. 2000 Jun;26(3):237-4210901116
Cites: Med Decis Making. 2000 Jul-Sep;20(3):332-4210929856